logo-loader
viewAcasti Pharma Inc

Acasti Pharma shares lifted as it further bolsters its intellectual property portfolio

Acasti revealed it has now been granted a second composition matter patent from the Canadian Intellectual Property office

Acasti Pharma Inc -
CaPre is aimed at treating hypertriglyceridemia - high levels of triglycerides in the blood - which is known to contribute to heart disease

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) told investors on Monday that it has further strengthened its intellectual property (IP) portfolio as it moves towards a potential launch of its drug CaPre, sending shares higher.

The company is developing CaPre, a krill-oil derived prescription drug, to treat hypertriglyceridemia - high levels of triglycerides in the blood - which is known to contribute to heart disease.

READ: Acasti Pharma shares nudge higher as it files meeting request with the US Food and Drug Administration

In a statement, the biotech firm said it has now been granted a second composition matter patent from the Canadian Intellectual Property office.

This new patent expands its existing claims to include any composition containing eicosapentaenoic acid (EPA) found in certain fish oils and DHA (Docosahexaenoic acid ), an omega-3 fatty acid where at least 50% of the composition consists of phospholipids, it said.

"This notice of Allowance for a composition of matter patent builds upon similar patents previously awarded in the United States and Mexico, expanding the scope of our composition claims," said Pierre Lemieux, Acasti's chief operating officer and chief scientific officer.

"Strengthening our IP portfolio is central to our business strategy as we move forward with commercial launch planning, assuming we are successful in gaining regulatory approval for CaPre.”

Meeting request filed

As reported on April 1, Acasti has now filed a meeting request with the US Food and Drug Administration (FDA) and expects this to take place in the second half of June.

The firm has carried out two Phase III trials on the drug - TRILOGY 1 and TRILOGY 2 - and identified some "unexpected and inconsistent findings" in the TRILOGY 1 trial that it believes may have negatively contributed to the overall topline results. Following that, Acasti announced an audit and analysis of the study data.

"The meeting is intended to discuss TRILOGY 1 data, and gain alignment with the FDA on the interpretation of the results," Acasti said at the beginning of this month.

Acasti shares in Toronto added 6.74% to C$0.95 on Monday morning.

Contact the author at [email protected]

Quick facts: Acasti Pharma Inc

Price: 0.79 CAD

TSX-V:ACST
Market: TSX-V
Market Cap: $73.07 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc named herein, including the promotion by the Company of Acasti Pharma Inc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Acasti has 'put its finger on something very interesting' in...

Acasti Pharma Inc (NASDAQ:ACST)(CVE:ACST) COO Pierre Lemieux tells Proactive the last patient completed their final visit in its TRILOGY 1 trial of lead drug CaPre, which treats severe hypertriglyceridemia. Lemieux says the Quebec-based company is on its way to reporting results by the end of...

on 26/11/19

2 min read